 Jason Kolfenbach
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 8 | 2025 | 118 | 1.900 |
Why?
| | Rheumatic Diseases | 3 | 2023 | 81 | 0.950 |
Why?
| | Takayasu Arteritis | 1 | 2025 | 16 | 0.950 |
Why?
| | Non-ST Elevated Myocardial Infarction | 1 | 2025 | 22 | 0.930 |
Why?
| | Arthritis, Rheumatoid | 9 | 2023 | 1167 | 0.870 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 460 | 0.730 |
Why?
| | Triage | 1 | 2019 | 222 | 0.520 |
Why?
| | Autoantibodies | 6 | 2015 | 1496 | 0.430 |
Why?
| | Education, Medical, Graduate | 4 | 2025 | 486 | 0.390 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 84 | 0.340 |
Why?
| | Telemedicine | 3 | 2025 | 862 | 0.340 |
Why?
| | Hydrolases | 1 | 2010 | 48 | 0.330 |
Why?
| | Myelitis | 1 | 2011 | 107 | 0.330 |
Why?
| | Granulomatosis with Polyangiitis | 2 | 2020 | 44 | 0.320 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 293 | 0.320 |
Why?
| | Neuromyelitis Optica | 1 | 2011 | 132 | 0.320 |
Why?
| | Family Health | 1 | 2009 | 196 | 0.300 |
Why?
| | Peptides, Cyclic | 5 | 2015 | 259 | 0.290 |
Why?
| | Rheumatoid Factor | 4 | 2015 | 175 | 0.270 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 622 | 0.260 |
Why?
| | Formative Feedback | 1 | 2025 | 28 | 0.230 |
Why?
| | Scleroderma, Diffuse | 1 | 2025 | 10 | 0.230 |
Why?
| | Drug-Eluting Stents | 1 | 2025 | 81 | 0.230 |
Why?
| | Echocardiography, Transesophageal | 1 | 2025 | 96 | 0.230 |
Why?
| | Curriculum | 4 | 2023 | 992 | 0.220 |
Why?
| | Coronary Artery Bypass | 1 | 2025 | 234 | 0.210 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 890 | 0.200 |
Why?
| | Coronary Angiography | 1 | 2025 | 317 | 0.200 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 5 | 0.200 |
Why?
| | Corneal Ulcer | 1 | 2022 | 16 | 0.190 |
Why?
| | Scleritis | 1 | 2022 | 23 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2426 | 0.190 |
Why?
| | Electrocardiography | 1 | 2025 | 629 | 0.190 |
Why?
| | Methotrexate | 3 | 2021 | 260 | 0.180 |
Why?
| | Rheumatologists | 2 | 2023 | 16 | 0.180 |
Why?
| | Autoimmunity | 3 | 2012 | 908 | 0.180 |
Why?
| | Educational Status | 1 | 2023 | 470 | 0.180 |
Why?
| | Humans | 24 | 2025 | 137585 | 0.160 |
Why?
| | Aftercare | 1 | 2021 | 208 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 480 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 91 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 242 | 0.150 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.140 |
Why?
| | Patient Selection | 2 | 2019 | 696 | 0.140 |
Why?
| | Behcet Syndrome | 1 | 2016 | 18 | 0.130 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.130 |
Why?
| | Azathioprine | 1 | 2016 | 54 | 0.130 |
Why?
| | Patient Readmission | 1 | 2021 | 697 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2016 | 56 | 0.120 |
Why?
| | Eye Diseases | 1 | 2016 | 87 | 0.120 |
Why?
| | Female | 13 | 2025 | 73304 | 0.120 |
Why?
| | Drug Costs | 1 | 2016 | 106 | 0.120 |
Why?
| | Vision Disorders | 1 | 2016 | 142 | 0.120 |
Why?
| | Glucocorticoids | 2 | 2016 | 594 | 0.120 |
Why?
| | Uveitis | 1 | 2016 | 136 | 0.110 |
Why?
| | Disease Progression | 2 | 2011 | 2757 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1178 | 0.100 |
Why?
| | Health Care Costs | 1 | 2016 | 398 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2011 | 37 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2025 | 238 | 0.090 |
Why?
| | Middle Aged | 9 | 2025 | 33479 | 0.090 |
Why?
| | Internship and Residency | 1 | 2022 | 1147 | 0.090 |
Why?
| | Chemokines | 1 | 2012 | 228 | 0.090 |
Why?
| | C-Reactive Protein | 2 | 2012 | 410 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 852 | 0.090 |
Why?
| | Protein-Arginine Deiminases | 1 | 2010 | 16 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1692 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1313 | 0.080 |
Why?
| | Patient Care Planning | 1 | 2011 | 157 | 0.080 |
Why?
| | Risk Factors | 4 | 2025 | 10388 | 0.080 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2009 | 46 | 0.080 |
Why?
| | Fellowships and Scholarships | 2 | 2023 | 306 | 0.080 |
Why?
| | Male | 10 | 2025 | 67762 | 0.080 |
Why?
| | Prospective Studies | 3 | 2025 | 7604 | 0.070 |
Why?
| | Aged | 6 | 2025 | 23961 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2526 | 0.060 |
Why?
| | Clinical Competence | 2 | 2025 | 1118 | 0.060 |
Why?
| | Lung Diseases | 1 | 2011 | 767 | 0.060 |
Why?
| | Antilymphocyte Serum | 1 | 2025 | 66 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2031 | 0.060 |
Why?
| | Feedback | 1 | 2025 | 173 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2025 | 247 | 0.050 |
Why?
| | Inflammation | 2 | 2012 | 2837 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 117 | 0.050 |
Why?
| | Cohort Studies | 2 | 2012 | 5742 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2844 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 280 | 0.050 |
Why?
| | Biological Factors | 1 | 2022 | 39 | 0.050 |
Why?
| | Focus Groups | 1 | 2025 | 522 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2189 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 83 | 0.050 |
Why?
| | Needs Assessment | 1 | 2023 | 376 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2021 | 66 | 0.040 |
Why?
| | Young Adult | 2 | 2021 | 13209 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 24 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6828 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 151 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 113 | 0.040 |
Why?
| | Internal Medicine | 1 | 2022 | 265 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1946 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 161 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 176 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 307 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 238 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.040 |
Why?
| | Biomarkers | 1 | 2009 | 4149 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 10811 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 21513 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3284 | 0.030 |
Why?
| | United States | 2 | 2016 | 14841 | 0.030 |
Why?
| | Administration, Topical | 1 | 2016 | 151 | 0.030 |
Why?
| | Specialization | 1 | 2016 | 144 | 0.030 |
Why?
| | Ophthalmology | 1 | 2016 | 86 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 171 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 565 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 283 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 5778 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 322 | 0.030 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 152 | 0.020 |
Why?
| | Patient Care Team | 1 | 2016 | 631 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 455 | 0.020 |
Why?
| | Joints | 1 | 2011 | 105 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 789 | 0.020 |
Why?
| | Decision Making | 1 | 2016 | 900 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 778 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2074 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 2085 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2021 | 15657 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3196 | 0.010 |
Why?
| | Child | 1 | 2016 | 21935 | 0.010 |
Why?
|
|
Kolfenbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|